Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | AGEN1777 + unspecified PD-1 antibody |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AGEN1777 | AGEN-1777|AGEN 1777 | TIGIT Antibody 19 | AGEN1777 is a bispecific antibody that targets both TIGIT and an undisclosed receptor expressed on T-lymphocytes and NK cells, which blocks TIGIT interaction with CD112 and CD155, which results in increased interaction of CD112 and CD155 with the co-stimulatory receptor CD226 and activation of downstream signaling, potentially inducing an anti-tumor immune response (NCI Drug Dictionary). | |
unspecified PD-1 antibody | Experimental PD-1 antibody | Immune Checkpoint Inhibitor 147 PD-L1/PD-1 antibody 117 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05025085 | Phase I | AGEN1777 AGEN1777 + unspecified PD-1 antibody | A Study Investigating AGEN1777 in Participants With Advanced Solid Tumors | Active, not recruiting | USA | 0 |